; (B) safety or efficacy for new or repurposed currently approved drugs for CCM treatment; (C) research related to improving and measuring the quality of life for individuals with CCM and their families; (D) contributions of genetic variation to clinical presentation as targets for therapy; (E) early detection, diagnosis, and treatment of CCM; (F) clinical training programs aimed at increasing the number of scientists and clinicians who are trained to treat patients and carry out the research described in this paragraph; (G) continued development and expansion of novel animal models for preclinical research relating to CCM; (H) preclinical and clinical research related to repurposing currently approved drugs for CCM treatment; (I) proteomic, pharmacological, and cell biological analysis of CCM molecules; (J) biological mechanisms for lesion genesis, development, and maturation; (K) biological mechanisms for lesion bleeding and symptomology; (L) novel biomedical and pharmacological interventions designed to inhibit new lesion development, lesion growth, and lesion bleeding; (M) novel biomedical and pharmacological interventions designed to target existing lesions to reduce their size and clinical activity; (N) continued research related to understanding better the natural history and clinical variation associated with CCM, particularly as it relates to the development of drug development tools and clinical outcome assessments; (O) the gut-brain axis and the effects of microbiome composition on clinical symptom­ology; and (P) the microbiome as a therapeutic target for CCM treatment. (2) Facilitation of research resources